C-terminal fragment of apolipoprotein E and its application in inhibiting γ-secretase activity

By inhibiting the γ-secretase cleavage activity of the C-terminal fragment of apolipoprotein E and reducing Aβ production, the unknown risk of apolipoprotein E isoforms to AD has been solved, achieving therapeutic effects for AD and amyloidosis, and extending to other disease areas.

CN116554303BActive Publication Date: 2026-11-10SYNPHATEC (SHANGHAI) BIOPHARMACEUTICAL TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202210113320.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-30
Publication Date
2026-11-10
Estimated Expiration
2042-01-30

AI Technical Summary

Technical Problem

It remains unclear how apolipoproteins E2 and E4 affect the risk of developing Alzheimer's disease, and existing drugs targeting gamma secretase have limited efficacy in treating AD.

Method used

A C-terminal fragment of apolipoprotein E is provided, which reduces Aβ production and increases the production of non-amyloid metabolite α-CTF by directly inhibiting the enzymatic activity of γ-secretase. When applied to neurons, the fragment is expressed in the brain of AD model mice by fusing a membrane-penetrating peptide with the C-terminal fragment of ApoE2 using an AAV expression system.

Benefits of technology

This study slows down the formation of amyloid plaques and reduces Aβ production in AD model mice, providing a novel γ-secretase inhibitor for the prevention and treatment of AD and amyloid cerebrovascular disease, and its potential applications in various diseases such as cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_8
    Figure SMS_8
  • Figure SMS_9
    Figure SMS_9
  • Figure SMS_10
    Figure SMS_10
Patent Text Reader

Abstract

This invention relates to the C-terminal fragment of apolipoprotein E and its application in inhibiting the activity of γ-secretase. The isolated polypeptide provided by this invention is selected from: (1) a fragment of the amino acid sequence shown in SEQ ID NO:12, wherein the first amino acid residue at the N-terminus of the fragment is an amino acid residue at any position from SEQ ID NO:12 to position 215-221, and the last amino acid residue at the C-terminus is an amino acid residue at any position from SEQ ID NO:12 to position 274-299; (2) a polypeptide in which one or more amino acids have been substituted, deleted, or added to the amino acid sequence of the fragment described in (1), or whose amino acid sequence has at least 70% sequence identity with the fragment described in (1), while retaining the inhibitory activity of the polypeptide in (1) on γ-secretase. This invention also provides the coding sequence of the polypeptide, nucleic acid constructs, host cells, pharmaceutical compositions, and applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the C-terminal fragment of apolipoprotein E and its application in inhibiting the activity of γ-secretase. Background Technology

[0002] Gamma-secretase is a cleaving enzyme that cuts more than 90 type I transmembrane proteins and participates in a variety of biological processes. Abnormal T-cell and B-cell differentiation, hemorrhagic diarrhea, skin and hair defects, and Alzheimer's disease (AD) are all associated with abnormalities in gamma-secretase. Gamma-secretase is a complex of four proteins: NCT, APH1, PEN2, and presenilin 1 (PS1) or presenilin 2 (PS2). The cleavage active site of gamma-secretase is either PS1 or PS2. Many mutations in PS1 and PS2 have been found to cause AD. Both PS1 and PS2 are pathogenic genes for AD; therefore, gamma-secretase is a very important drug target, especially for the treatment of AD.

[0003] Alzheimer's disease (AD) is one of the most common neurodegenerative diseases in humans. AD patients mainly exhibit progressive memory impairment, cognitive dysfunction, personality changes, and language disorders, which further progress to loss of self-care ability and ultimately death.

[0004] Over the past few decades, significant progress has been made in understanding the pathogenesis of Alzheimer's disease (AD), leading to the Aβ cascade hypothesis. This hypothesis posits that the excessive production and abnormal accumulation of Aβ in the brain is the initiating cause of a series of severe and slow-growing pathological changes, resulting in abnormal biological processes within the brain, leading to synaptic degeneration and neuronal death. Aβ is produced from amyloid precursor protein (APP) through the sequential cleavage of β and γ secretases. In the brain, APP is expressed by neurons, and after Aβ is generated, it is released extracellularly—a process known as the amyloid metabolic pathway of APP. Under normal physiological conditions, the Aβ produced in the brain is mostly soluble. However, in pathological conditions, Aβ abnormally accumulates in large quantities, forming amyloid plaques deposited around neurons, causing neuronal damage, further leading to brain tissue deterioration, and ultimately resulting in AD. Furthermore, the abnormal accumulation and deposition of amyloid protein in cerebral blood vessels can trigger amyloidosis. In addition to being cleaved by β and γ secretases to produce toxic Aβ, APP can also be sequentially cleaved by α and γ secretases. Because the α-secretase cleavage site is located inside Aβ, the α-secretase product does not generate Aβ, and the cleaved fragments are not neurotoxic and do not cause AD; it is a non-amyloid metabolic pathway of APP. α and β cleavage compete with each other; increasing α-secretase cleavage decreases Aβ production. Similarly, reducing γ-secretase cleavage also reduces Aβ production, slows the formation of amyloid plaques, and ultimately slows down or even prevents the occurrence of AD and amyloid cerebrovascular disease. Several drugs targeting γ-secretase have undergone clinical trials.

[0005] Apolipoprotein E (ApoE) is a widely secreted protein in the human body, and it can be co-expressed with APP in neurons in the brain. Human ApoE has three isoforms: ApoE2, ApoE3, and ApoE4. They are highly similar in structure and function, roughly divided into three functional domains: an N-terminal domain containing a receptor-binding site, a C-terminal domain containing a lipid-binding site, and a flexible hinge region connecting the two domains. ApoE2, ApoE3, and ApoE4 differ only in two amino acid residues in the N-terminal domain; their amino acid sequences in the C-terminal domain are identical. ApoE2 has a protective effect, reducing the risk of Alzheimer's disease (AD); ApoE4 is the most significant risk factor for AD, not only significantly increasing the risk of AD but also significantly advancing the age of onset and worsening the condition.

[0006] To date, it remains unclear how ApoE2 and ApoE4 alter the risk of developing Alzheimer's disease. Summary of the Invention

[0007] The first aspect of this invention provides an isolated polypeptide selected from: (1) A fragment of the amino acid sequence shown in SEQ ID NO:12, wherein the first amino acid residue at the N-terminus of the fragment is an amino acid residue at position 215, 216, 217, 218, 219, 220 or 221 of SEQ ID NO:12, and the last amino acid residue at the C-terminus is an amino acid residue at any position from position 274 to 299, preferably from position 279 to 299 of SEQ ID NO:12; (2) A polypeptide in which one or more amino acids are substituted, deleted or added to the amino acid sequence of the fragment in (1) while retaining the γ-secretase cleavage activity of the polypeptide in (1), or a polypeptide whose amino acid sequence has at least 70% sequence identity with the fragment in (1) and retains the γ-secretase cleavage activity of the polypeptide in (1).

[0008] In one or more embodiments, the amino acid sequence includes at least the amino acid sequence shown in SEQ ID NO:32.

[0009] In one or more embodiments, the amino acid sequence of the polypeptide is as described in any of SEQ ID NO:13 and 18-33.

[0010] A second aspect of the present invention provides a fusion protein comprising the following elements (1) and (2): Component (1): membrane-penetrating peptide, and Element (2): The full-length sequence of ApoE2 or a fragment of ApoE2 including at least amino acid residues 221-274 of SEQ ID NO:12; The elements (1) and (2) are directly connected by peptide bonds or by adapter sequences.

[0011] In one or more embodiments, the membrane-penetrating peptide is selected from: RQIKIWFQNRRMKWKK (SEQ ID NO:35); YGRKKRRQRRR (SEQ ID NO:36); KQAIPVAK (SEQ ID NO:37); RRRRNRTRRNRRRVR (SEQ ID NO:38); Oligoarginine (R9-R) 12 ); KLTRAQRRAAARKNKRNTRGC (SEQ ID NO:39); ALWKTLLKKVLKAPKKKRKVC(SEQ ID NO:40); RKKRRQRRR (SEQ ID NO:41); DAATATRGRSAASRPTERPRAPARSASRPRRPVE (SEQ ID NO:42); GWTLNSAGYLLGKINLKALAALAKKIL(SEQ ID NO:43); AGYLLGKINLKALAALAKKIL (SEQ ID NO:44); and YTAIAWVKAFIRKLRK (SEQ ID NO:45); In one or more embodiments, the fragment of ApoE2 comprising at least amino acid residues 221-274 of SEQ ID NO:12 of element (2) is selected from: the polypeptide described in any embodiment herein, and the fragment containing the N-terminal and hinge region of ApoE2 and at least amino acid residues 221-274 of the C-terminus; preferably, the fragment containing the N-terminal and hinge region of ApoE2 and at least amino acid residues 221-274 of the C-terminus is selected from: SEQ ID NO:12. NO:12 amino acid residues 1-274, amino acid residues 1-279, and amino acid residues 1 to 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, or 299.

[0012] In one or more embodiments, the amino acid sequence of the fragment of element (2) is as described in any of SEQ ID NO:13 and 18-33.

[0013] A third aspect of this invention provides a nucleic acid molecule selected from: (1) A nucleic acid molecule encoding the isolated polypeptide or fusion protein described in any embodiment of this document; or (2) (1) The full-length complementary sequence of the nucleic acid molecule.

[0014] A fourth aspect of the present invention provides a nucleic acid construct containing the nucleic acid molecule described in any of the embodiments herein.

[0015] In one or more embodiments, the nucleic acid construct is an expression cassette, a cloning vector, or an expression vector.

[0016] A fifth aspect of the present invention provides a vector containing a neuron-specific promoter and: (1) The coding sequence of the isolated polypeptide as described in claim 1 or 2; or (2) The encoding sequence of ApoE2; or (3) The coding sequence of the ApoE2 fragment.

[0017] In one or more embodiments, the expression vector is a recombinant AAV expression vector.

[0018] In one or more embodiments, the amino acid sequence of the polypeptide is as described in any of SEQ ID NO:13 and 18-33.

[0019] In one or more embodiments, the amino acid sequence of the ApoE2 is shown in SEQ ID NO: 12.

[0020] In one or more embodiments, the ApoE2 fragment is a fragment of the ApoE2 of claim 3 that includes at least amino acid residues 221-274 of SEQ ID NO:12, selected from: the polypeptide described in any embodiment herein, and a fragment containing the N-terminal and hinge region of ApoE2 and at least amino acid residues 221-274 of the C-terminus; preferably, the fragment containing the N-terminal and hinge region of ApoE2 and at least amino acid residues 221-274 of the C-terminus is selected from: SEQ ID NO:12. NO:12 amino acid residues 1-274, amino acid residues 1-279, and amino acid residues 1 to 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, or 299.

[0021] In one or more embodiments, the neuron-specific promoter is selected from synaptic protein promoters, Thy-1 promoters, and calmodulin-dependent protein kinase II-α promoters, etc.

[0022] A sixth aspect of the present invention provides a host cell that expresses a polypeptide or fusion protein as described in any embodiment herein, and / or contains a nucleic acid molecule or nucleic acid construct or vector as described in any embodiment herein.

[0023] In one or more embodiments, the host cell is a neuron.

[0024] A seventh aspect of the present invention provides a pharmaceutical composition comprising a polypeptide, fusion protein, nucleic acid molecule, nucleic acid construct or carrier as described in any embodiment herein, and a pharmaceutically acceptable carrier.

[0025] The seventh aspect of the present invention provides the use of the polypeptide, fusion protein, nucleic acid molecule, nucleic acid construct, vector, host cell, or pharmaceutical composition described in any embodiment herein in the preparation of a medicament for treating or preventing diseases in which the enzymatic activity of γ-secretase is inhibited.

[0026] In one or more embodiments, the disease is selected from: neurodegenerative diseases, tumors or cancers, inflammatory diseases, and kidney diseases.

[0027] In one or more embodiments, the disease is selected from: Alzheimer's disease, amyloid angiopathy, Down syndrome, head and neck cancer (such as squamous cell carcinoma of the head and neck and squamous cell carcinoma of the oral cavity), breast cancer, liver cancer, pancreatic cancer (including metastatic pancreatic cancer), ovarian cancer, lung cancer (such as non-small cell lung cancer, lung adenocarcinoma and small cell lung cancer), glioma (such as malignant glioma), fibroma, lymphoma (such as B-cell lymphoma), osteosarcoma, gastric cancer, bladder cancer, asthma (such as allergic asthma), pneumonia, airway inflammation, and acute kidney injury. Attached Figure Description

[0028] Figure 1ApoE attenuates amyloid metabolism of APP via its C-terminal fragment (ApoE CT) while increasing its non-amyloid metabolites (α-CTF). A and B: Transient transfection of ApoE2 and ApoE3 into HEK 293T cells via liposomes significantly increased α-CTF production from co-expressed APP via the non-amyloid metabolic pathway (α-cleavage), while ApoE4 did not. Statistical results are in B, N=8, paired or one sample t-test. C: Transient transfection of ApoE2 attenuated total Aβ40 production decreased, N=8, paired or one sample t-test. D and E: Immunoblotting showed that overexpression of ApoE CT increased α-CTF production from co-expressed APP, while overexpression of the N-terminal fragments of ApoE2 and ApoE4 (ApoE NT) did not alter α-CTF production. Statistical results are in E, N=8, paired or one sample t-test. F and G: Overexpression of ApoECT reduced Aβ40 and Aβ42 generated by APP, while overexpression of ApoE2 NT, ApoE3 NT, or ApoE4 NT did not change Aβ. N=5, one sample t-test. AG: HEK 293T cells. H: Expression of ApoE CT using a lentivirus in primary cultured neurons of the mouse cerebral cortex and hippocampus reduced the concentration of secreted endogenous Aβ40. The promoter was hSyn. N=7, one sample t-test. I: ApoE CT expressed using lentivirus in human neurons induced from pluripotent stem cell lines also reduced the secretion of endogenous Aβ40. The promoter was hSyn, N=5, unpaired t-test. Western blot detection of proteins APP, α-CTF, and ApoE; Aβ was detected by ELISA.

[0029] Figure 2A: ApoE2 and ApoE CT in the culture medium do not increase the non-amyloid metabolites of APP in cells. B: Western blotting assay detected ApoE2 and ApoE CT proteins in the culture medium. C: Co-incubation with cell culture medium containing ApoE2 or ApoE CT proteins did not change the α-CTF generated by APP in cells. Statistical results are in C, N=9, one samplet-test. D: Immunofluorescence assay showed that after co-incubation of HEK 293T cells with cell culture medium containing ApoE2 or ApoE CT proteins, no large amounts of ApoE or ApoE CT proteins were detected intracellularly; only a small portion adhered to the surface of individual cells. However, ApoE CT, transiently expressed in HEK 293T cells using liposomes, was abundant intracellularly. E: Immunofluorescence experiments showed that after co-incubation with culture medium containing ApoE2 or ApoE CT proteins, no large amounts of ApoE or ApoE CT proteins were detected in primary cultured mouse neurons; only a small portion adhered to the surface of individual neurons. However, ApoE CT expressed using lentiviruses was abundant within neurons. ApoE2 and ApoE CT are shown in green; MAP2-labeled neurons are shown in red; and DAPI-labeled cell nuclei are shown in blue.

[0030] Figure 3 The core sequence of ApoE CT that reduces Aβ production. A, B, and C: Effects of overexpression of different ApoE CT mutants on Aβ production by APP in HEK 293T cells. A: CT NA1 / 2 / 3 / 4 / / 5: Addition of 1, 2, 3, 4, or 5 amino acid residues from the N-terminus of ApoE CT. CT ND3 / 4: Deletion of 3 or 4 amino acid residues from the N-terminus of ApoE CT. CTCD5 / 10: Deletion of 5 or 10 amino acid residues from the C-terminus of ApoE CT. ELISA was used to measure the effect of different ApoE CT mutants on the concentration of Aβ40 secreted into the culture medium. B: CT ND1 / 2 / / 5: Deletion of 1, 2, or 5 amino acid residues from the N-terminus of ApoE CT. ELISA was used to measure the effect of different ApoE CT mutants on the concentration of Aβ40 in cell lysate. C: CT ND3CD10 / 11 / 12 / 13 / 14 / 15 / 20 / 25: This involves deleting 3 amino acid residues at the N-terminus of ApoE CT, along with 10, 11, 12, 13, 14, 15, 20, or 25 amino acids at the C-terminus. ELISA was used to measure the effect of different ApoE CT mutants on the concentration of Aβ40 in cell lysates. N=5 (A, B) or 7 (C), one sample t-test.

[0031] Figure 4Overexpression of ApoE CT in HEK 293T cells did not alter the mRNA (A) and protein expression levels of APP secretases (B). ADAM10: α-secretase of APP; BACE1: β-secretase of APP; PS1 and PS2: core active subunit proteins of γ-secretase. mRNA and protein levels were detected using qRT-PCR and Western Blot, respectively. Cells expressing GFP served as a negative control. N=9, one sample t-test.

[0032] Figure 5 In HEK 293T cells, overexpression of ApoE CT mimics the effect of γ-secretase inhibitors on APP cleavage and inhibits γ-CTF cleavage. A and B: Overexpression of the γ-secretase active site protein PS1 reduces α-CTF production, while ApoE CT expression or treatment with 1 μM PF03084014 (a γ-secretase inhibitor) increases α-CTF production. Statistical results are in B, N=11, paired or one-sample t-test. C and D: Overexpression of ApoE CT inhibits the production of Aβ40 (N=4) and Aβ42 (N=6) from β-CTF, one-sample t-test. E: Overexpression of ApoE CT does not affect APP. ΔAICD Aβ40, generated by β-enzyme digestion, N=4, was used for one-sample t-test. The protein was detected by Western blotting, and Aβ was detected by ELISA.

[0033] Figure 6 ApoE CT affects APP cleavage and requires the presence of γ-secretase. A and D: In HEK 293T cells (PS1 / 2 dKO) where the active sites of γ-secretase, PS1 and PS2, were knocked out, α-CTF increased significantly, but overexpression of ApoE CT did not further increase α-CTF. The statistical results are shown in Figure D. B, C, and D: In PS1 / 2 dKO cells supplemented with PS1 or PS2 expression, overexpression of ApoE CT restored the increase in α-CTF. The statistical results are shown in Figure D, N=8, paired t-test. E: In PS1 / 2 dKO cells supplemented with PS2 expression, overexpression of ApoE CT reduced Aβ40 generated by APP, N=4, one sample t-test. Protein was detected by Western blot, and Aβ40 was detected by ELISA.

[0034] Figure 7A: In vitro purified ApoE2 directly inhibited γ-cleavage of APP in a concentration-dependent manner. Western blot showed the separation and purification of β-CTF, ApoE2, ApoE2 NT, PS1, NCT, PEN2, and GFP. B: In the purified system, the reaction of γ-secretase cleavage of β-CTF to generate Aβ40 could be completely inhibited by 10 μM PF03084014 (γ-secretase inhibitor), N=3, paired t-tests. C: Purified ApoE2 inhibited γ-secretase cleavage of β-CTF in a dose-dependent manner, reducing Aβ40 production. The measured half-maximal inhibitory concentration (HIC) of ApoE2 was approximately 1.2 μM, N=3. D: Purified ApoE2 inhibited the formation of Aβ40 from β-CTF via γ-cleavage, but ApoE2 NT did not inhibit γ-secretase cleavage of β-CTF, N=3, paired t-tests. Protein was detected by Western blot, and Aβ40 was detected by ELISA.

[0035] Figure 8 ApoE CT does not inhibit APLP1 γ-cleavage. 1 μM PF03084014 (γ-secretase inhibitor) inhibited the γ-cleavage of APLP1 expressed in HEK 293T cells and increased the α-like CTF generated by APLP1 α-cleavage; however, co-expression of ApoE CT with APLP1 did not increase the α-like CTF of APLP1.

[0036] Figure 9 Overexpression of ApoE CT in neurons of a 5xFAD mouse model using an adeno-associated virus (AAV) expression system reduced amyloid plaques. A: Representative images of co-staining amyloid plaques (THS, red) and ApoE CT (green) or GFP (green) in the subiculum region of a 5xFAD mouse model. ApoE CT was expressed in 5xFAD mice using AAV (injected at 1 month of age, analyzed at 7 months of age), with GFP as a control and hSyn as the promoter. Statistical results are shown in B, C, D, and E. B: Mice expressing ApoE CT showed smaller average area (B), weaker average fluorescence intensity (C), smaller proportion of total area (D), and lower plaque density per amyloid plaque in the subiculum region (E). THS was used to label the amyloid plaques. N=33, unpaired t-test. Detailed Implementation

[0037] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form preferred technical solutions.

[0038] In this article, human apolipoprotein E (ApoE) includes ApoE2, ApoE3, and ApoE4. An exemplary amino acid sequence of ApoE2 is shown below: KVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRD ADDLQKCLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH (SEQ ID NO:12).

[0039] This application is the first to discover that apolipoprotein E (ApoE), through its C-terminal fragment, inhibits the enzymatic cleavage of γ-secretase in a cell-autonomous manner (i.e., functions within the same cell as γ-secretase), thereby inhibiting amyloid metabolism of APP and reducing Aβ production; it also increases the non-amyloid metabolite of APP, α-CTF; and slows the size and density of amyloid plaques in the brains of AD model mice. Therefore, the C-terminal fragment of ApoE can serve as a drug targeting γ-secretase for slowing or preventing the occurrence and development of AD and amyloidosis. Furthermore, as an inhibitor of γ-secretase, the C-terminal fragment of ApoE may play a role in various biological processes, and its application is not limited to neurodegenerative diseases but can also be used for various diseases such as cancer.

[0040] This application further discovers that the amino acid sequence from positions 221 to 274 of SEQ ID NO:12 in the C-terminal fragment of apolipoprotein E is an essential amino acid sequence for the C-terminal fragment to perform its biological function. Furthermore, this invention discovers that the shortest functional fragment in the C-terminal fragment of apolipoprotein E is the amino acid sequence from positions 220 to 274 of SEQ ID NO:12, and preferably the shortest fragment is: EMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGL (SEQ ID NO: 12, amino acid residues 220-279, SEQ ID NO: 34).

[0041] Therefore, this application provides an isolated polypeptide, which is a C-terminal fragment of the ApoE protein. It should be understood that the term "fragment" as used herein refers to a continuous amino acid sequence from the corresponding protein. The amino acid sequence of the polypeptide of this invention begins at amino acid residues 215, 216, 217, 218, 219, 220, or 221 of ApoE, preferably at residues 215, 216, 219, 220, or 221, and ends at residues 274 to 299 of ApoE (i.e., residues 274, 275, 276, 277, 278, and 279). The amino acid sequence at positions 221-274 of SEQ ID NO:12 is preferred. The amino acid sequence at positions 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, and 299 is preferred. The polypeptide of the present invention comprises at least the amino acid sequence at positions 221-274 of SEQ ID NO:12, preferably at least the amino acid sequence shown in SEQ ID NO:34, more preferably at least the amino acid sequence shown in SEQ ID NO:32, and even more preferably at least the amino acid sequence shown in SEQ ID NO:31.

[0042] The amino acid sequences of exemplary polypeptides are shown in any of SEQ ID NO:13 and 18-33.

[0043] The polypeptides described in this application also include mutants thereof, which have “conserved modifications” compared to the polypeptide. The term “conserved modification” refers to amino acid modifications that do not significantly affect or alter the polypeptide’s inhibition of γ-secretase cleavage. Such conserved modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies of the present invention using standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. In some embodiments, the mutant has one or more (e.g., up to 10, 8, 5, or 3) amino acid insertions, substitutions, and / or deletions compared to the polypeptide, while still retaining the polypeptide’s biological activity of inhibiting γ-secretase cleavage.

[0044] Preferably, the conserved modification is a conserved substitution. A conserved substitution refers to the substitution of an amino acid residue by an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with the following side chains: basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0045] In some embodiments, the mutant shares at least 80% sequence identity with the polypeptide, preferably at least 85%, at least 90%, at least 95%, at least 96%, 97%, 98%, or 99%. Preferably, the polypeptide sharing this sequence identity also inhibits γ-secretase cleavage and / or is also derived from humans. The sequence identity between the mutant and the polypeptide can be determined using methods known in the art, for example, BLASTP assay.

[0046] In some embodiments, the present invention provides a fusion protein comprising the following elements (1) and (2): (1) a transmembrane peptide, and (2) the full-length sequence of ApoE2 or a fragment of ApoE2 including at least amino acid residues 221-274 of SEQ ID NO:12. The elements (1) and (2) may be directly linked by peptide bonds or by adapter sequences.

[0047] In this document, the term "membrane-penetrating peptide" or "cell-penetrating peptide" as a fusion protein element (1) refers to a class of short peptides capable of carrying macromolecules into cells. Membrane-penetrating peptides known in the art can be used to construct the fusion protein of this invention. An exemplary membrane-penetrating peptide can be found in Siegmund Reissmann, Cell penetration: scope and limitations by the application of cell-penetrating peptides, J. Pept. Sci. 2014;20:760–784. The entire contents of which are incorporated herein by reference. In particular, the membrane-penetrating peptides applicable to the present invention include, but are not limited to, RQIKIWFQNRRMKWKK (SEQ ID NO:35); YGRKKRRQRRR (SEQ ID NO:36); KQAIPVAK (SEQ ID NO:37); RRRRNRTRRNRRRVR (SEQ ID NO:38); oligoarginine (i.e., fragments with 9-12 arginine residues); KLTRAQRRAAARKNKRNTRGC (SEQ ID NO:39); ALWKTLLKKVLKAPKKKRKVC (SEQ ID NO:40); RKKRRQRRR (SEQ ID NO:41); DAATATRGRSAASRPTERPRAPARSASRPRRPVE (SEQ ID NO:42); GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:43); AGYLLGKINLKALAALAKKIL (SEQ ID NO:44); and YTAIAWVKAFIRKLRK (SEQ ID NO:45).

[0048] The ApoE2 of element (2) comprising at least the 221-274th amino acid residues of SEQ ID NO:12 (also referred to herein as the ApoE2 fragment, to distinguish it from the isolated polypeptide, i.e. the C-terminal fragment, described herein) may include the isolated polypeptide (i.e. the C-terminal fragment) described in any embodiment herein, as well as a fragment containing the N-terminal and hinge regions of ApoE2 and at least the 221-274th amino acid residues of the C-terminus. An exemplary ApoE2 fragment may be, for example, amino acid residues 1-274, amino acid residues 1-279 of SEQ ID NO:12, and amino acid residues 1 to 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, or 299.

[0049] In some implementations, element (2) is selected from: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:18-33.

[0050] In this document, the linker is typically a peptide of 3 to 25 residues, such as peptides of 3 to 15, 5 to 15, or 10 to 20 residues. Suitable examples of peptide linkers are well known in the art. Typically, the linker contains one or more repeating motifs, which typically contain Gly and / or Ser. For example, the motif can be SGGS, GSSGS, GGGS, GGGGS, SSSSG, GSGSA, and GGSGG. Preferably, the motifs are adjacent in the linker sequence, with no inserted amino acid residues between the repeats. The linker sequence can consist of 1, 2, 3, 4, or 5 repeating motifs. In some embodiments, the linker sequence is a polyglycine linker sequence. The number of glycine residues in the linker sequence is not particularly limited, typically 2 to 20, such as 2 to 15, 2 to 10, or 2 to 8. In addition to glycine and serine, the linker may also contain other known amino acid residues, such as alanine, leucine, threonine, glutamic acid, phenylalanine, arginine, glutamine, etc.

[0051] The fusion protein of the present invention may also include amino acid residues or sequences introduced into the fusion protein due to gene cloning operations, and / or for constructing the fusion protein, promoting the expression of recombinant protein, obtaining recombinant protein that is automatically secreted outside the host cell, or facilitating the detection and / or purification of recombinant protein.

[0052] This application also includes nucleic acid molecules encoding the aforementioned polypeptides or fusion proteins and their complementary sequences. This invention includes all forms of the nucleic acid molecules of this invention, including RNA and DNA. It should be understood that the complementary sequence referred to herein is a complementary sequence of substantially the same length as the nucleic acid molecule.

[0053] Nucleic acid constructs containing the said nucleic acid molecule or its complementary sequence are also included within the scope of this invention. The nucleic acid construct may be an expression cassette containing a promoter, the said nucleic acid molecule, and a transcription termination sequence. Optionally, the expression cassette may also contain an enhancer, depending on the expression requirements. Promoters, enhancers, and transcription termination sequences are well known in the art and can be appropriately selected by those skilled in the art based on the chosen host cell for expressing the polypeptide. These elements in the expression cassette are operatively linked to each other to enable them to perform their intended functions. For example, operatively linking a promoter sequence to a nucleotide sequence of interest means linking the promoter sequence and the nucleotide sequence of interest so that the promoter sequence can direct transcription of the nucleotide sequence of interest in the target cell and / or the synthesis of the polypeptide encoded by the nucleotide sequence of interest.

[0054] In a particularly preferred embodiment, the gene expression control element suitable for use in this invention is a neuron-specific control element, including a promoter and an enhancer. Hereinafter, the term "neuron-specific" refers to a control element, such as a promoter and enhancer, used for the specific expression of a nucleic acid molecule of interest in a neuron. In some embodiments, a neuron-specific promoter is a promoter used for expressing a transgene in a specific subtype of neuron (e.g., dopaminergic neurons, excitatory neurons, lateral prefrontal cortex neurons, etc.).

[0055] Neuron-specific promoters and other control elements (such as enhancers) are known in the art. Suitable neuron-specific promoters include, but are not limited to, neuron-specific enolase (NSE) promoters, aromatic amino acid decarboxylase promoters, neurofilament promoters, synaptic protein promoters, Thy-1 promoters, serotonin receptor promoters, tyrosine hydroxylase promoters, GnRH promoters, L7 promoters, DNMT promoters, enkephalin promoters, myelin basic protein promoters, calmodulin-dependent protein kinase II-α promoters, and CMV enhancers / platelet-derived growth factor-β promoters.

[0056] In some implementations, nucleic acid constructs are vectors, including expression vectors and cloning vectors. Expression vectors are suitable for expressing exogenous genes, such as nucleic acid molecules encoding the polypeptides described in this invention (e.g., the full-length sequence of ApoE2 or the C-terminal fragment of the ApoE protein described herein), in host cells. These vectors include prokaryotic and eukaryotic expression vectors. Eukaryotic expression systems include yeast expression systems, mammalian cell expression systems, and insect cell expression systems. Cloning vectors are used to amplify target genes (such as nucleic acid molecules encoding the polypeptides described in this invention) in host cells. Cloning vectors include plasmid vectors, phage vectors, viral vectors, and vectors composed of combinations of these or other genomic DNA. The most commonly used host cell in molecular cloning is *Escherichia coli*.

[0057] In some embodiments, the vector is a viral vector, including but not limited to lentiviral vectors, herpes simplex virus vectors, adenovirus vectors, and adeno-associated virus (AAV) vectors. Such vectors can be prepared using standard methods in the art.

[0058] In some embodiments, the vector is a recombinant AAV vector. The AAV vector can be prepared using standard methods in the art. Any serotype of adeno-associated virus vector can be used, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, and AAV16.

[0059] In some embodiments, the present invention provides a vector containing an expression cassette containing a neuron-specific promoter operatively linked to a nucleic acid molecule of interest, selected from: nucleic acid molecules encoding the C-terminal fragment of the present invention, nucleic acid molecules encoding the full-length ApoE2 protein, and nucleic acid molecules encoding the ApoE2 fragment of the present invention. Preferably, the vector is a recombinant AAV vector. Preferably, neuron-specific promoters suitable for use herein include synaptic protein promoters, Thy-1 promoters, and calmodulin-dependent protein kinase II-α promoters. In some embodiments, the nucleic acid molecule of interest encodes any of the amino acid sequences shown in SEQ ID NO: 12, 13, and 18-33.

[0060] The present invention also provides an expression system comprising the nucleic acid molecules, nucleic acid constructs, or vectors disclosed herein. The expression system may be, for example, a Gram-positive or Gram-negative prokaryotic host cell system, such as *Escherichia coli* modified to express the polypeptides of the present invention. In some embodiments, the expression system is a eukaryotic host cell system, such as yeast, for example, *Pichia pastoris* or *Saccharomyces cerevisiae*.

[0061] In some embodiments, the present invention also includes neurons containing nucleic acid molecules, nucleic acid constructs or vectors disclosed herein, or expressing the polypeptides described herein.

[0062] The present invention also provides a pharmaceutical composition comprising: (1) the C-terminal fragment or a mutant thereof as described in any embodiment of the present invention, (2) the fusion protein of the present invention, or (3) the carrier of the present invention, and a pharmaceutically acceptable carrier.

[0063] The actual dose level of the active ingredient (i.e., the C-terminal peptide, fusion protein, or expression vector of the present invention) in the pharmaceutical composition can be varied to obtain an amount of active ingredient that effectively achieves the desired therapeutic response for a specific patient, composition, and administration method, without toxicity to the patient. The selected dose level will depend on a variety of pharmacokinetic factors, including the activity of the peptide or expression vector used in the present invention, the route of administration, the time of administration, the duration of treatment, other drugs, compounds, and / or substances used in combination with the specific composition used, the age, sex, weight, condition, general health, and prior medical history of the patient being treated, and similar factors well known in the medical field.

[0064] In this article, pharmaceutically acceptable carriers include diluents, adjuvants, excipients, or solvents, including but not limited to water, animal oils, vegetable oils, starch, glucose, lactose, sucrose, gelatin, sodium stearate, glyceryl monostearate, sodium chloride, skim milk powder, glycerin, propylene, propylene glycol, water, ethanol, etc. If desired, the composition may also contain small amounts of wetting agents or emulsifiers, or pH buffers.

[0065] In this article, the pharmaceutical composition may be in the form of solution, suspension, emulsion, tablet, pill, capsule, powder, sustained-release formulation, etc. The polypeptides of this invention can be prepared into suitable dosage forms according to specific methods and routes of administration.

[0066] In this article, appropriate methods and routes of administration are known in the art. Appropriate routes of administration include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other parenteral administration routes, such as injection or infusion. “Parenteral administration” is a mode of administration other than enteral and local administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrasheath, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, nasal, tracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, spinal, epidural, and intrasternal injections and infusions.

[0067] In some embodiments, the pharmaceutical compositions of the present invention are introduced into the central nervous system via any suitable route, including intraventricular and intrathecal injection. Intraventricular injection may be assisted via, for example, an intraventricular catheter connected to a reservoir (e.g., the Ommaya reservoir).

[0068] In some embodiments, nucleic acid molecules encoding the polypeptides of the present invention, such as the coding sequence of the polypeptides of the present invention, including RNA and DNA sequences, may be delivered using techniques known in the art. In some embodiments, the coding sequence of the polypeptides of the present invention is delivered to a desired subject in the form of an expression vector (e.g., using a viral vector). In some embodiments, liposomes are used to deliver the DNA or RNA molecules described herein that can encode the polypeptides of the present invention. Therefore, in these embodiments, the pharmaceutical compositions of the present invention contain liposomes and the DNA or RNA molecules described herein that encode the polypeptides of the present invention and their expression vectors. The liposomes suitable for the present invention can be any liposomes known in the art suitable for human administration.

[0069] The polypeptides of the present invention are inhibitors of γ-secretase, and therefore the polypeptides of the present invention or pharmaceutical compositions thereof may be used to treat or prevent diseases that benefit from the inhibition of γ-secretase, diseases that are targeted to inhibit γ-secretase to obtain therapeutic or preventive benefits (also referred to herein as γ-secretase-mediated diseases). Several diseases are known to be mediated by gamma-secretase, including: neurodegenerative diseases such as Alzheimer's disease and amyloid angiopathy (Erik D. Roberson and Lennart Mucke, 100 years and Counting: Prospects for Defeating Alzheimer's Disease, 314: 781-784 (2006); Bart De Strooper et al., Presenilins and γ-Secretase: Structure, Function, and Role in Alzheimer's Disease, 2:a006304 (2012); Weiming Xia, γ-Secretase and its modulators: Twenty years and beyond, Neuroscience Letters 701: 162–169 (2019)); tumors or cancers, including head and neck cancers such as head and neck squamous cell carcinoma and oral squamous cell carcinoma (Liang Mao et al., γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumor immunity in head and neck squamous cells). carcinoma, Int. J.Cancer: 142, 999–1009 (2018)), breast cancer and hepatocellular carcinoma (Hui Jia et al., γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment, LifeSciences 268 (2021) 119007), pancreatic cancer (including metastatic pancreatic cancer) (Ana De Jesus-Acosta et al., APhase II Study of the Gamma Secretase Inhibitor RO4929097 in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma, Invest New Drugs. 2014 August; 32(4): 739–745), ovarian cancer (Zhaoyi Feng, Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer, Oncotarget, 2017, Vol. 8, (No. 5), pp: 8215-8225), lung cancer (such as non-small cell lung cancer or lung adenocarcinoma and small cell lung cancer) (Antonio Maraver, Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma through derepression of DUSP1 phosphatase and inhibition of ERK, Cancer Cell. 2012 August 14; 22(2); Katherine M. Morgan et al., Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma, Mol Cancer Ther.2017 December; 16(12): 2759–2769), gliomas such as malignant gliomas (Edward Pan et al., Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma, Neurooncol.2016 December; 130(3): 571–579), JOURNAL OF CLINICAL ONCOLOGY, VOLUME35, NUMBER 14, MAY 10, 2017), lymphomas such as B-cell lymphoma (Shuji Tohda, Establishment of anovel B-cell lymphoma cell line with suppressed growth by gamma-secretaseinhibitors, Leukemia Research 30 (2006) 1385–1390), gastric cancer (Hyun-Woo Lee et al., Targeting Notch signaling by c-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer, Clin Exp Metastasis (2015) 32:593–603), bladder cancer (YIBING WANG et al., γ-secretase inhibitor inhibits bladder cancer cell drug resistance and invasion by reducing epithelial-mesenchymal transition, MOLECULAR MEDICINE REPORTS 12: 2821-2827, 2015), osteosarcoma (M Tanaka et al., Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation, British Journal of Cancer (2009) 100, 1957–1965); inflammatory diseases, including asthma, such as allergic asthma (Weixi Zhang et al., ). -Secretase Inhibitor Alleviates Acute Airway Inflammation of Allergic Asthma in Mice by Downregulating Th17 Cell Differentiation, Mediators of Inflammation, Volume 2015, Article ID 258168, 7 pages), airway inflammation such as allergic airway inflammation (Weixi Zhang et al., -Secretase Inhibitor Alleviates Acute AirwayInflammation of Allergic Asthma in Mice by Downregulating Th17 CellDifferentiation, Mediators of Inflammation, Volume 2015, Article ID 258168), pneumonia (Jin Hyun Kang et al., g-Secretase Inhibitor Reduces Allergic PulmonaryInflammation by Modulating Th1 and Th2 Responses, AMERICAN JOURNAL OFRESPIRATORY AND CRITICAL CARE MEDICINE VOL 179, 2009), etc.; kidney diseases, such as acute kidney injury (Jean-Christophe Wyss et al., Targeted γ-secretase inhibition of Notch signaling activation in acute renal injury, Am J Physiol Renal Physiol 314: F736–F746, 2018).

[0070] Therefore, the present invention also provides a method for treating or preventing γ-secretase-mediated diseases in a subject, the method comprising administering to the subject a therapeutically or preventively effective amount of the polypeptide, fusion protein, nucleic acid molecule, carrier, or pharmaceutical composition thereof of the present invention. The effective amount can be determined by those skilled in the art based on factors such as the subject's age, sex, weight, condition, general health, and prior medical history. The diseases preferably include, as described above, neurodegenerative diseases, tumors or cancers, inflammatory diseases, and kidney diseases.

[0071] Some embodiments of the present invention provide a method for inhibiting the enzymatic cleavage of adenosine monophosphate (A2) secretase, thereby inhibiting APP amyloid metabolism and reducing Aβ production. This method includes generating ApoE2 or a C-terminal fragment of ApoE2 as described in any embodiment herein within a cell expressing A2 secretase. In some embodiments, the cell is a neuron. In some embodiments, the method is used to slow, prevent, or treat the occurrence and development of Alzheimer's disease (AD) and amyloidosis. The generation described herein includes expressing the generating polypeptide and delivering the polypeptide into the cell from outside the cell. In some embodiments, liposomes are used to deliver DNA or RNA encoding the ApoE2 and / or its C-terminal fragment into the cell, causing intracellular expression of the ApoE2 and / or its C-terminal fragment; or lentiviruses and adeno-associated viruses are used to generate the ApoE2 and / or its C-terminal fragment within the cell; or cell transmembrane peptides or endocytosis-enhanced methods are used to allow the ApoE2 and / or its C-terminal fragment to enter the cell.

[0072] In some embodiments, the present invention also provides the use of the polypeptides, fusion proteins, nucleic acid molecules, vectors or host cells described herein in the preparation of medicaments for treating or preventing γ-secretase-mediated diseases described herein, as well as the polypeptides, fusion proteins, nucleic acid molecules, vectors or pharmaceutical compositions thereof described herein for treating or preventing γ-secretase-mediated diseases described herein.

[0073] In some embodiments, the polypeptides mentioned in the fusion proteins, uses and methods described in any of the embodiments described herein specifically include any of the polypeptides shown in SEQ ID NO: 12, 13 and 18-33.

[0074] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Furthermore, it should be understood that after reading the teachings of this invention, those skilled in the art can make various alterations or modifications to the invention, and these equivalent forms also fall within the scope defined by the appended claims.

[0075] In this example, data were analyzed using GraphPad Prism software, and all data are presented as mean ± SEM. The following data analysis used unpaired, paired, or one-sample t-tests. Significant differences are indicated by an asterisk (...). ) display, an asterisk ( ) indicates a p-value less than 0.05; two asterisks ( ) indicates a p-value less than 0.01; three asterisks ( ) indicates a p-value less than 0.001; four asterisks ( () indicates that the P-value is less than 0.0001.

[0076] Example 1

[0077] 1. Main reagents and materials

[0078] HEK 293T cell lines were cultured in DMEM medium (HyClone) containing 10% fetal bovine serum (FBS) (Life) and 1% penicillin / streptomycin, and then in a sterile cell culture incubator at 37°C containing 5% CO2 (ThermoFisher).

[0079] Primary cultured neurons were derived from the cortex or hippocampus of 16-day-old embryonic mice. Mouse cortex or hippocampus was obtained under a stereomicroscope; digestion was performed at 37°C for 10 minutes with 20 U / ml papain (Worthington); neurons present as single cells after digestion were seeded at 100,000 neurons per well (24-well plate); the neurons were cultured in neurobasal medium (ThermoFisher) containing 2% B27 (ThermoFisher) and 1% penicillin / streptomycin; the culture medium was changed weekly.

[0080] C57 wild-type mice aged 0-7 months and AD model mice (5×FAD mice [Tg6799], expressing pathogenic mutations in APP and PS1. APP has three mutations: K670N / M671L, I716V, and V717I; PS1 has two mutations: M146L and L286V). Mice were provided with ample food and water and housed at room temperature with a 12h / 12h light / dark cycle, meeting SPF (Specific Pathogen Free) standards.

[0081] Enzyme-linked immunosorbent assay kits (ELISA) were purchased from Invitrogen, including human Aβ40 (KHB3481), human Aβ42 (KHB3441), and mouse Aβ40 (KMB3481).

[0082] The transfection reagents were lipofectamine 2000 from ThermoFisher and Polyjet from SignaGen.

[0083] The Quantitect SYBR-Green qRT-PCR kit for qRT-PCR was purchased from Qiagen.

[0084] Table 1: Antibody Information

[0085] 2. Experimental Methods

[0086] 2.1 Protein Sample Preparation and Western Blot

[0087] a) Construct a plasmid for expressing the target protein in mammalian cells, with the protein expression promoter being CAG.

[0088] b) Expression of the target protein in the HEK 293T cell line. Cells were passaged one day before transfection, and transfection was performed when cell adhesion reached 70%-80%. The transfection reagent was Lipofectamine 2000 (Thermo Fisher Scientific).

[0089] c) Replace with fresh cell culture medium 4-6 hours after transfection.

[0090] d) 36-48 hours after transfection, lyse the cells (10% 1M tris-HCl (pH=6.8), 4% SDS, 20% glycerol, 0.01% bromophenol blue), collect protein samples, and then proceed with immunoblotting or freeze at -80°C.

[0091] e) Polyacrylamide gel electrophoresis. Before loading proteins, boil at 98°C for 10 min, then centrifuge at 12000 rpm for 10 min. Electrophoresis: stacking gel 80 V; separating gel 120 V.

[0092] f) Transfer. Before use, wet the filter paper in the electrophoresis solution. Activate the PVDF membrane in methanol for 10 seconds. Remove the gel after electrophoresis from the electrophoresis tank and arrange it in the following order from bottom to top: filter paper-PVD membrane-gel-filter paper. Place it in the transfer apparatus and transfer at a constant current of 0.1 A for 70 minutes.

[0093] g) Blocking and antibody incubation: Place the converted PVDF membrane in 5% BSA / TBST blocking solution and block on a shaker at room temperature for 1 h. Incubate with primary antibody at 4°C on a shaker overnight (12-16 h); wash three times with 1×TBST, 10 minutes each time; incubate with secondary antibody on a shaker at room temperature for 1-2 h; wash three times with 1×TBST, 10 minutes each time.

[0094] h) Imaging: ECL chemiluminescent ultrasensitive colorimetric reagent is used for development.

[0095] 2.2 Brain slice preparation and immunohistochemistry

[0096] a) Brain harvesting via perfusion. Mice were perfused through the heart. Blood was first rinsed off with 20 ml of PBS, followed by perfusion with 20 ml of 4% PFA.

[0097] b) Fixation and dehydration. First, fix with 4% PFA at 4°C for 24 hours, then dehydrate with 30% sucrose at 4°C.

[0098] c) Mouse brain slices. After dehydration for 24 hours, mouse brains were sliced ​​into 40 μm thick slices and stored in cryopreservation buffer or used for subsequent immunohistochemistry.

[0099] d) THS staining. Wash three times with ddH2O, 5 minutes each time; soak in 1% THS aqueous solution for 10 minutes; wash twice with 80% ethanol, 3 minutes each time; wash once with 95% ethanol, 3 minutes each time. Proceed with subsequent immunohistochemistry. If THS staining is not performed, proceed directly to the following immunohistochemistry.

[0100] e) Immunohistochemistry. Wash three times with 1×PBS, 10 minutes each time; permeabilize cells with 0.1% Triton-X100; block cells with 5% donkey or goat serum; then incubate with primary antibody at 4°C on a shaker overnight (12-16 h); wash three times with 1×PBS, 10 minutes each time; incubate with secondary antibody at room temperature on a shaker for 1-2 h; wash three times with 1×PBS, 10 minutes each time.

[0101] f) Patch mounting and sealing.

[0102] g) Imaging, 24 hours after mounting.

[0103] h) Use ImageJ to process images and analyze signal density.

[0104] 2.3 Enzyme-linked immunosorbent assay (ELISA)

[0105] The experiment was conducted according to the standard procedure in the Invitrogen ELISA assay kit.

[0106] a) Expression of the target protein in the HEK 293T cell line. Cells were passaged one day before transfection, and transfection was performed when cell adhesion reached 70%-80%. The transfection reagent was Lipofectamine 2000 (Thermo Fisher Scientific).

[0107] b) Replace with fresh culture medium 4-6 hours after transfection; c) 36-48 hours after transfection, collect the cell culture medium and then proceed with the ELISA process or freeze it at -80°C.

[0108] d) Add 50 μL of standard sample and experimental sample to each well of the 96-well plate.

[0109] e) Add 50 μL of human Aβ40 or Aβ42 or mouse Aβ40 detection antibody to each well of a 96-well plate.

[0110] f) Shake gently and let stand at room temperature for 3 hours.

[0111] g) Remove the liquid from the well and wash 4 times with 1×wash buffer.

[0112] h) Add 100 ml of buffer containing 1× anti-Rabbit IgG HRP.

[0113] i) Shake gently and let stand at room temperature for 30 minutes.

[0114] j) Remove the liquid from the well and wash 4 times with 1×wash buffer.

[0115] k) Add 100 ml of Stabilized Chromogen to each well and incubate at room temperature in the dark for 30 minutes.

[0116] l) Add 100 ml of Stop Solution to each well.

[0117] The absorbance at 450 nm was measured using an enzyme-linked immunosorbent assay (ELISA) reader.

[0118] 2.4 qRT-PCR

[0119] RNA was extracted from the treated cells according to the TRIzol™ Reagent (ThermoFisher) manual.

[0120] a) Expression of the target protein in the HEK 293T cell line. Cells were passaged one day before transfection, and transfection was performed when cell adhesion reached 70%-80%. The transfection reagent was Lipofectamine 2000 (Thermo Fisher Scientific).

[0121] b) Replace with fresh culture medium 6 hours after transfection.

[0122] c) RNA was extracted 48 hours after transfection.

[0123] d) Add 500 ml of Trizol (ThermoFisher) to each well of the 24-well plate, shake, and incubate at room temperature for 20 minutes.

[0124] e) Collect the cell suspension into centrifuge tubes.

[0125] f) Add 250 ml of chloroform, invert thoroughly to mix, and let stand at room temperature for 3 minutes.

[0126] (g) 12000g, centrifuged at 4℃ for 15 minutes. After centrifugation, the solution showed obvious stratification: the bottom layer was chloroform containing phenol (pink), the middle layer was DNA and protein, and the top layer was an aqueous phase containing RNA (clear and transparent). The supernatant was transferred to a new centrifuge tube.

[0127] h) Add an equal volume of isopropanol (supernatant), invert to mix, and let stand at room temperature for 20 minutes.

[0128] i) Centrifuge at 12000g, 4℃ for 15 minutes. Remove the supernatant; a small amount of white precipitate (RNA) will be visible at the bottom.

[0129] j) Add 400 μL of 75% ethanol. Centrifuge at 12000 g for 5 minutes at 4°C.

[0130] k) Remove as much ethanol as possible and thoroughly dry the fume hood, but avoid over-drying. Add an appropriate amount of DEPC water.

[0131] l) After removing DNA, store at -80℃ for subsequent experiments.

[0132] The relative mRNA content was quantitatively analyzed using the Qiagen Quantitect SYBR-Green qRT-PCR kit. The qRT-PCR primers are shown in Table 2.

[0133] Table 2: Primers used for qRT-PCR

[0134] 2.5 Construction of PS1 KO, PS2 KO and PS1 / 2 dKO cell lines

[0135] We selected HEK 293T cells and constructed PS1 KO, PS2 KO, and PS1 / 2 dKO cell lines using CRISPR / CAS9 technology according to the standard procedure published by Zhang Feng et al. in 2013. We designed sgRNAs specifically for knocking out PS1 and PS2 using the website https: / / zlab.bio / guide-design-resources, as shown in Table 3.

[0136] a) PS2 sgRNA and control empty plasmid were expressed in HEK 293T cells. Cells were passaged one day before transfection, and transfection was performed when cell adhesion reached 70%-80%. The transfection reagent was lipofectamine 2000 (Thermo Fisher Scientific).

[0137] b) Replace with fresh culture medium 6 hours after transfection.

[0138] c) 18 hours after transfection, replace with fresh culture medium containing 3 mg / ml puromycin (Sellect).

[0139] d) After all HEK 293T cells transfected with the empty plasmid died under the action of 3 μg / ml puromycin, HEK 293T cells transfected with PS2 sgRNA were collected.

[0140] e) Transfect HEK 293T cells transfected with PS2 sgRNA at a ratio of 1:400 into 10 cm cell culture dishes to ensure that the cells proliferate in a monoclonal form.

[0141] f) Once the monoclonal cells have grown to a cell cluster, collect the individual cell clusters and passage them into 12-well plates.

[0142] g) Once the cell clusters have fully colonized the 12-well plate, collect the cells. Half of the cells are used to extract DNA and protein, and to detect the DNA sequence and protein expression levels of PS2 cells. The other half of the cells are used for passage.

[0143] h) Cells whose PS2 DNA sequence has been edited and which no longer express the PS2 protein are PS2 knockout cell lines—PS2 KO cell lines.

[0144] i) We constructed the PS1 / PS2 dKO cell line based on the PS2 KO cell line. PS1 sgRNA and a control empty plasmid were expressed in the PS2 KO cell line; and the ag step was performed to detect the DNA sequence and protein expression of PS1.

[0145] j) PS2 KO cell lines in which the PS1 DNA sequence has been edited and the PS1 protein is no longer expressed are PS1 / PS2 double knockout cell lines.

[0146] Table 3: sgRNA

[0147] 2.6 Virus preparation and injection.

[0148] 2.6.1 Lentiviral Preparation

[0149] a) Construct lentivirus expression plasmids, lentivirus-GFP and lentivirus-ApoE CT, that can be specifically expressed in neurons.

[0150] b) Incorporate the lentiviral expression vector with the capsid protein vector (PSPA) X2 and PMD 2GThe cells were co-transfected into the HEK 293T cell line. Cells were passaged one day before transfection, and transfection was performed when cell adhesion reached 70%-80%. The transfection reagent was Polyjet (SignaGen).

[0151] c) 36-48 hours after transfection, collect the cell culture medium and filter it through a 0.22 mm filter membrane.

[0152] d) Centrifuge the filtered cell culture medium at 20,000 rpm, 4°C for 2 hours and 5 minutes.

[0153] e) After centrifugation, remove the supernatant and resuspend the precipitate of every 3 x 10 cm cell culture media in 50 μl of PBS.

[0154] f) The resuspended virus was aliquoted and stored in a -80°C freezer for subsequent experiments.

[0155] 2.6.2 Preparation of adeno-associated virus

[0156] Adeno-associated viruses AAV-CT (AAV2 / 9-hSyn-ApoE CT) and AAV-GFP (AAV2 / 9-hSyn-EGFP-WPRE-pA) expressed in neurons were purchased from Telto Biotechnology Co., Ltd.

[0157] 2.6.3 Virus Injection

[0158] The adeno-associated virus (AAV) prepared in 1 μl was injected into the cerebral cortex (x, y, z, + / -1.6, 0, -1) and hippocampus (x, y, z, + / -1.5, -2, -1.5) of 1-month-old mice using a stereotactic injection device.

[0159] 2.7 Protein purification

[0160] 2.7.1 Purification of γ-secretase

[0161] The expression plasmid for human γ-secretase was obtained from Professor Yigong Shi's research group at Westlake University.

[0162] a) Human γ-secretase was expressed in the HEK 293T cell line (the same expression plasmid simultaneously expressed four proteins of human γ-secretase: NCT, PS1, PLAG-PEN2, and APH). Cells were passaged one day before transfection, and transfection was performed when cell adhesion reached 70%-80%. The transfection reagent was Lipofectamine 2000 (Thermo Fisher Scientific).

[0163] b) Replace with fresh cell culture medium 4-6 hours after transfection.

[0164] c) 48 hours after transfection, wash once with ice-cold 1×PBS, scrape the cells off with a cell scraper, collect the cells by centrifugation at 800g for 5min.

[0165] d) Lyse and resuspend cells with lysis buffer [25 mM HEPES, pH 7.4; 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 0.05% (v / v) Tween-20, 1×cocktail].

[0166] e) Sonicate the lysed cells for 20 cycles (3 seconds on, 3 seconds off), 45% power output.

[0167] f) Centrifuge at 3000g, 4℃ for 10 minutes, and collect the supernatant into a new centrifuge tube.

[0168] 15000g, centrifuged at 4℃ for 1 hour, and the supernatant was discarded.

[0169] h) Resuspend the precipitate in 1 ml of lysis buffer, add 1% CHAPSO, and incubate at 4°C for 2 hours. Centrifuge at 15000g for 30 minutes and collect the supernatant into a new centrifuge tube.

[0170] i) Add 100 μl of FLAG beads (SIGMA) to the supernatant and incubate at 4°C for 2 hours.

[0171] j) Wash three times with the following buffer solution: 25 mM HEPES, pH 7.4; 150 mM NaCl, 0.1% digitonin.

[0172] k) Elute human γ-secretase with the following buffer: 25 mM HEPES, pH 7.4; 150 mM NaCl, 0.1% digitonin, and 500 μg / ml 3xFLAG peptide (SIGMA).

[0173] l) Immunoblotting detection of purified human γ-secretase; stored at -80℃.

[0174] 2.7.2 Purification of ApoE

[0175] a) ApoE2 and ApoE2 NT were expressed in the HEK 293T cell line. Both ApoE2 and ApoE2 NT proteins contain a fusion-expressed FLAG. Cells were passaged one day before transfection, and transfection was performed when cell adhesion reached 70%-80%. The transfection reagent was lipofectamine 2000 (Thermo Fisher Scientific).

[0176] b) Replace with fresh cell culture medium 4-6 hours after transfection.

[0177] c) 48 hours after transfection, wash once with ice-cold 1×PBS, scrape the cells off with a cell scraper, collect the cells by centrifugation at 800g for 5min.

[0178] d) Lyse and resuspend cells using lysis buffer [25 mM HEPES, pH 7.4; 150 mM NaCl, 1×cocktail].

[0179] e) Sonicate the lysed cells for 20 cycles (3 seconds on, 3 seconds off), 45% power output.

[0180] f) Centrifuge to obtain the supernatant containing protein, 12000g, 15 minutes, 4℃, and collect the supernatant into a new centrifuge tube.

[0181] g) The protein-containing supernatant was incubated with anti-FLAG M2 affinity resin (SIGMA) for 90 minutes at 4°C. After incubation, ApoE2 and ApoE2 NT were transferred to the anti-FLAG M2 affinity resin.

[0182] h) The anti-FLAG M2 affinity resin containing ApoE2 and ApoE2 NT was washed three times with the following buffer: 25 mM MEPES, pH 7.4; 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 0.05% (v / v) Tween-20.

[0183] i) ApoE2 and ApoE2 NT were eluted using the following buffer: 25 mM HEPES, pH 7.4; 150 mM NaCl and 500 μg / ml 3xFLAG peptide (SIGMA).

[0184] j) Immunoblotting detection of purified ApoE2 and ApoE2 NT; stored at -80℃.

[0185] 2.7.3 Purification of β-CTF

[0186] a) Express β-CTF in *E. coli* using the expression plasmid pET22β-CTF-Myc-6xHis.

[0187] b) After induction with 0.5 mM IPTG and expression at 37°C for 4 hours, *E. coli* was lysed using the following lysis buffer: 30 mM Tris-HCl, pH 7.5; 150 mM NaCl, 1 mM EDTA.

[0188] c) Centrifuge at 25000g at room temperature for 10 minutes. Remove the supernatant.

[0189] d) Resuspend the precipitate in the following buffer solution and mix slowly at room temperature: 30 mM Tris-HCl, pH 8.0; 300 mM NaCl, 1 mM EDTA, 6 M urea, 1% Triton X-100, 1 mM CaCl2, 1×cocktail.

[0190] e) Centrifuge at 40000g for 30 minutes, discard the precipitate, and filter the supernatant through a 0.45 mM filter membrane.

[0191] f) The filtered supernatant was incubated with Ni-NTA beads at room temperature for 2 hours. Then, the incubated Ni-NTA beads and supernatant were loaded into an empty chromatography column and allowed to flow out under gravity. The flow-through liquid was collected and then recombined with the beads once more.

[0192] g) Clean the Ni-NTA beads with 10 times the volume of the Ni-NTA bead column as follows: 30 mM Tris-HCl, pH 8.0; 300 mM NaCl, 1 mM EDTA, 6 M urea, 1% Triton X-100, 1 mM CaCl2, 1× cocktail.

[0193] h) Clean the Ni-NTA beads with 20 times the volume of the Ni-NTA bead column as follows: 30 mM Tris-HCl, pH 8.0; 300 mM NaCl, 0.1% Trion X-100.

[0194] i) Clean the Ni-NTA beads with 20 times the volume of the Ni-NTA bead column as follows: 50 mM Tris-HCl, pH 8.0; 300 mM NaCl, 0.1% CHAPSO.

[0195] j) Elute β-CTF with the following buffer: 50 mM Tris-HCl, pH 8.0; 300 mM NaCl, 0.1% CHAPSO, 300 mM imidazole.

[0196] k) Detect the purified β-CTF using immunoblotting; store at -80℃.

[0197] 2.7.4 Purification of GFP

[0198] The purification method for GFP is the same as that for ApoE in 2.7.2.

[0199] 3. Experimental Results

[0200] 3.1 Effects of three ApoE isoforms and different ApoE protein fragments on APP metabolism

[0201] We co-expressed human APP with ApoE2, ApoE3, and ApoE4 in HEK 293T cells, with GFP as the control group. Western blot was used to determine the amount of α-CTF produced. Immunoblot results ( Figure 1 (AB) showed that co-expression of ApoE2 and ApoE3 significantly increased the non-amyloid metabolites and α-CTF of APP; while expression of ApoE4 did not significantly alter α-CTF. We further investigated the effect of ApoE on the APP amyloid metabolic pathway. Aβ is a product of amyloid metabolism; the lower the amount of Aβ produced, the weaker the amyloid metabolism of APP. We co-expressed human wild-type APP and β-secretase with ApoE2, ApoE3, or ApoE4 in HEK 293T cells, with GFP as a control, and detected the effect of ApoE on Aβ production. ELISA results ( Figure 1 (C) shows that ApoE2 significantly reduced Aβ40 production, but ApoE3 and ApoE4 did not have this effect. Compared to ApoE4, ApoE2 also reduced Aβ40. These results indicate that ApoE2, expressed in the same cell line as APP, can attenuate APP's amyloid metabolism, reduce Aβ40, and increase APP's non-amyloid metabolite, α-CTF. ApoE4 does not possess this ability.

[0202] We further investigated which fragments of ApoE functioned to attenuate APP amyloid metabolism. ApoE2, ApoE3, and ApoE4 differed only in two amino acid residues in their N-terminal functional domain, while their C-terminal functional domains were identical. Therefore, we constructed expression plasmids for the N-terminal and C-terminal fragments of human ApoE, naming them ApoE2 NT, ApoE3 NT, ApoE4 NT, or ApoE CT protein plasmids for subsequent experiments. APP was co-expressed with ApoE2 NT, ApoE4 NT, and ApoE CT in HEK 293T cells, with GFP serving as the control group. Immunoblotting results (…) Figure 1 (DE) showed that only co-expression of ApoE CT significantly increased α-CTF to more than 5-fold of its original level. Co-expression of ApoE2 NT and ApoE4 NT did not change α-CTF. Meanwhile, ELISA results ( Figure 1 (FG) showed that ApoE CT significantly reduced Aβ40 to ~25% of the GFP control, while none of the three ApoE NTs reduced Aβ40; similarly, ApoE CT significantly reduced Aβ42 to ~26% of the GFP control.

[0203] AD is a neurological disorder in which Aβ is primarily produced by the cleavage of APP expressed in neurons. We constructed a lentivirus expressing ApoE CT in neurons. ELISA results ( Figure 1 (H) indicates that overexpression of ApoE CT in neurons can reduce endogenously generated Aβ40 in primary cultured mouse hippocampal or cortical neurons to ~71% and ~73% of the control group, respectively. Similarly ( Figure 1 ApoE CT overexpression in neurons also reduced endogenously generated Aβ40 in human pluripotent stem cell-induced neurons to ~54% of that in the control group.

[0204] These results demonstrate that in various cell types, ApoE2 can increase the non-amyloid metabolite of APP, α-CTF, in a cell-autonomous manner through its C-terminal fragment, while simultaneously weakening the amyloid metabolic pathway and reducing Aβ.

[0205] The ApoE CT amino acid sequences used in each experiment in this paper are as follows: ARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH (SEQ ID NO: 33).

[0206] 3.2 ApoE2 and ApoE CT secreted in the culture medium do not affect APP shearing.

[0207] HEK 293T cells expressing ApoE2 or ApoE CT were cultured, and the resulting culture medium showed that it contained secreted ApoE2 or ApoE CT. Figure 2 HEK293T cells expressing APP were co-incubated with a culture medium containing ApoE2 or ApoE CT. Results showed that, compared to the GFP control, the presence of ApoE2 and ApoE CT in the co-incubated culture medium did not alter α-CTF (ApoE2 and ApoE CT). Figure 2 , BC). Immunofluorescence results ( Figure 2 (DE) showed that even after prolonged co-incubation, ApoE2 and ApoE CT in the culture medium mainly adhered to the extracellular space and hardly entered the cell. In contrast, ApoE2 and ApoE CT expressed in cells or neurons can exist in large quantities inside the cell.

[0208] This result indicates that adding ApoE2 and ApoECT to cell culture medium does not alter the production of α-CTF and Aβ. ApoE2 and ApoECT must operate autonomously, meaning they must be present in the same cell as APP, to regulate APP cleavage and thus increase α-CTF and decrease Aβ production. Several methods can facilitate the entry of ApoE2 and ApoECT into target cells, including: liposome delivery of DNA or RNA encoding these proteins; lentiviral and adeno-associated virus infection of cells; cell transmembrane peptides; and enhanced endocytosis.

[0209] 3.3 Core sequences of ApoE CT that attenuate APP amyloid metabolism

[0210] To investigate which amino acids in ApoE CT are the core sequences that alter APP metabolism, we added 1, 2, 3, 4, or 5 amino acid residues from the original ApoE to the N-terminus of ApoE CT to construct plasmids expressing CT NA1, CT NA2, CT NA3, CT NA4, and CTNA5; deleted 1, 2, 3, 4, or 5 amino acids from the N-terminus of ApoE CT to construct plasmids expressing CT ND1, CT ND2, CT ND3, CT ND4, and CT ND5; and deleted 5 or 10 amino acids from the C-terminus of ApoE CT to construct plasmids expressing CT CD5 and CT CD10. The amino acid sequences of CT NA1, CT NA2, CT NA3, CT NA4, CT NA5, CT ND1, CT ND2, CT ND3, CT ND4, CT ND5, CT CD5, and CT CD10 are shown in SEQ ID NO:13-24.

[0211] SEQ ID NO:13 (CT NA1): RARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:14 (CT NA2): LRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:15(CT NA3): RLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:16(CT NA4): ERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:17(CT NA5): GERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:18(CT ND1): RMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:19(CT ND2): MEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:20(CT ND3): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:21(CT ND4): EMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:22(CT ND5): MGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH; SEQ ID NO:23 (CT CD5): ARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPV; SEQ ID NO:24 (CT CD10): ARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGT.

[0212] Human APP and β-secretase were co-expressed with each of the above plasmids in HEK 293T cells, with GFP as the control group. The effects of these proteins on the production of Aβ40 secretion were determined using ELISA. ELISA results ( Figure 3 (AB) The results showed that adding one amino acid residue to the N-terminus of ApoECT still reduced Aβ40 production with CT NA1; however, adding two or more amino acid residues completely eliminated the ability of CT NA2, CT NA3, CT NA4, and CT NA5 to reduce Aβ. Deleting one, two, or five amino acid residues from the N-terminus of ApoE CT still reduced Aβ40 in cell lysates with ApoE ND1, ApoE ND2, and ApoE ND5. Deleting three or four amino acid residues from the N-terminus of ApoE CT reduced Aβ40 secreted into the culture medium with ApoE ND3 and ApoE ND4. Even deleting 10 amino acid residues from the C-terminus of ApoE CT still reduced Aβ production with CTCD10. These results indicate that the N-terminus of ApoE CT is crucial, and even changes of only one or two amino acids can affect the inhibitory activity of ApoE CT on Aβ40 production. However, the effect of its C-terminal residues on activity is relatively weak.

[0213] Based on the above results, we deleted 3 amino acid residues (CT ND3) from the N-terminus of ApoE CT, and then deleted 10, 11, 12, 13, 14, 15, 20 or 25 amino acid residues from the C-terminus of ApoE CT, respectively, to construct plasmids expressing CTND3CD10, CT ND3CD11, CT ND3CD12, CT ND3CD13, CT ND3CD14, CT ND3CD15, CT ND3CD20 and CTND3CD25, the amino acid sequences of which are shown in SEQ ID NO:25-32.

[0214] SEQ ID NO:25 (CT ND3CD10): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGT; SEQ ID NO:26 (CT ND3CD11): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVG; SEQ ID NO:27 (CT ND3CD12): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAV; SEQ ID NO:28 (CT ND3CD13): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAA; SEQ ID NO:29 (CT ND3CD14): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQA; SEQ ID NO:30 (CT ND3CD15): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQ; SEQ ID NO:31 (CT ND3CD20): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGL; SEQ ID NO:32 (CT ND3CD25): EEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQR.

[0215] Human APP and β-secretase were co-expressed with each of the above plasmids in HEK 293T cells, with GFP as the control group. The effects of these proteins on Aβ production in cells were measured using ELISA. ELISA results ( Figure 3 (C) indicates that even after deleting 3 amino acid residues from the N-terminus or 10, 11, 12, 13, 14, 15, 20, or 25 amino acids from the C-terminus of ApoE CT, co-expression of CT ND3CD10, CT ND3CD11, CT ND3CD12, CT ND3CD13, CT ND3CD14, CT ND3CD15, CT ND3CD20, or CTND3CD25 still significantly reduces Aβ40. These results suggest that the core sequence of ApoE CT that inhibits Aβ generation ends at residue 274 to the last amino acid residue.

[0216] 3.4 ApoE CT affects APP shearing through γ-shearing

[0217] To investigate the mechanism by which ApoE CT affects APP cleavage, we examined whether ApoE CT alters the expression levels of key APP secretases. We used qRT-PCR and Western blotting to detect the mRNA and protein expression levels of ADAM10 (the major α-secretase), BACE1 (β-secretase), PS1, and PS2 (the active subunit of γ-secretase), respectively. qRT-PCR ( Figure 4 A) and Western Blot ( Figure 4 (B) The results showed that, compared with the GFP control, overexpression of ApoE CT in cells did not change the mRNA and protein expression levels of ADAM10, BACE1, PS1 and PS2, indicating that ApoE CT does not affect APP cleavage by changing the expression levels of APP metabolic enzymes.

[0218] α-CTF is a substrate of γ-secretase, while Aβ is a cleavage product of γ-secretase. Studies have found that inhibitors of γ-secretase lead to increased α-CTF and decreased Aβ. This result is similar to the activity of ApoE CT observed. Therefore, ApoE CT may mimic the effect of γ-secretase inhibitors. To verify this hypothesis, we co-expressed APP and the active site of γ-secretase, PS1, in HEK 293T cells. Immunoblotting results ( Figure 5 (AB) showed that overexpression of PS1 (which can enhance γ-secretase activity) decreased α-CTF. However, expression of ApoE CT or treatment with the 1 μM γ-secretase inhibitor PF03084014 significantly increased α-CTF. Figure 5 ,AB). This result suggests that the effect of ApoE CT expressed in cells on APP cleavage is similar to its effect on inhibiting γ-secretase. β-CTF is a product of APP cleavage by β-secretase and is also a substrate of γ-secretase; it can be converted to Aβ through a single γ-secretase step. ELISA results ( Figure 5 (CD) The results showed that expression of ApoE CT not only reduced Aβ40 generated by β-CTF to ~80% of its original level, but also reduced Aβ42 to ~8% of its original level; indicating that the ability of ApoE CT to reduce Aβ may be achieved by regulating γ-enzyme cleavage. We further expressed APP (APP intracellular C-terminal domain removed) ΔAICD APP is co-expressed with BACE1 and ApoE CT in HEK 293T cells. ΔAICD Aβ can be produced with just one step of β-digestion, without the need for γ-enzyme digestion. ELISA results ( Figure 5 E) shows that the expression ApoECT no longer decreases due to APP. ΔAICD The generated Aβ indicates that ApoE CT does not affect β-digestion.

[0219] These results suggest that ApoE CT expression in cells reduces Aβ only after γ-cleavage, and that overexpression of ApoE CT mimics the effect of γ-secretase inhibitors; ApoE CT may increase α-CTF and reduce Aβ by inhibiting γ-cleavage of APP.

[0220] 3.5 ApoE CT requires the presence of γ-secretase to affect APP shearing.

[0221] The active site of γ-secretase is either PS1 or PS2. After PS1 and PS2 are knocked out (PS1 / 2 dKO), α-CTF cannot be metabolized by γ-secretase cleavage, thus accumulating in large quantities. Immunoblotting results ( Figure 6(A, D) showed that ApoE CT expression significantly increased α-CTF in the wild-type HEK 293T cell line; in GFP-expressing PS1 / 2 dKO cells, α-CTF levels were significantly increased compared to the wild-type HEK 293T cell line. ApoE CT expression in PS1 / 2 dKO cells did not further increase α-CTF, indicating that ApoE CT no longer increases α-CTF in the absence of γ-secretase. However, ApoE CT expression in PS1 / 2 dKO cells supplemented with PS1 or PS2 significantly increased α-CTF, indicating that ApoE CT's increase in α-CTF is dependent on either PS1 or PS2. Similarly, in PS1 / 2 dKO cell lines supplemented with PS2 expression, overexpression of ApoE CT reduced Aβ40 (… Figure 6 These results indicate that ApoE CT can only regulate APP metabolism in the presence of γ-secretase.

[0222] 3.6 ApoE can directly inhibit the cleavage of β-CTF by γ-secretase in the purification system.

[0223] To further verify whether ApoE directly inhibits γ-secretase, we purified β-CTF, ApoE2, ApoE2 NT, and γ-secretase, and immunoblotting confirmed the efficacy of these purified proteins. Figure 7 (A). PS1, NCT, and PEN2 are constituent proteins of γ-secretase. ELISA results ( Figure 7 (B) shows that co-incubation of γ-secretase with β-CTF produces Aβ, which can be almost completely blocked by 10 μM γ-secretase inhibitor PF03084014. Adding purified ApoE2 to this reaction system also inhibits Aβ40 production in a concentration-dependent manner, with an IC50 of ~1.2 μM (B). Figure 7 C). Furthermore, under the same concentration conditions (2.5 μM), ApoE2 significantly inhibited Aβ production, but ApoE2 NT could not inhibit Aβ40 production. Figure 7 These results indicate that ApoE2 can directly inhibit the cleavage of β-CTF by γ-secretase, and that ApoE CT is essential for this activity of ApoE, suggesting that ApoE CT is a key fragment for ApoE2 to inhibit the cleavage of APP by γ-secretase.

[0224] 3.7 ApoE CT does not inhibit APLP1 γ-cleavage.

[0225] APLP1 (APP-like protein 1) is a protein structurally similar to APP and is also a substrate for α and γ secretases. Immunoblotting results ( Figure 8The results showed that the inhibitor PF03084014 of γ-secretase could inhibit the γ-cleavage of APLP1, resulting in a significant increase in α-like CTF; however, co-expressed ApoE CT did not increase the α-like CTF of APLP1, indicating that ApoE CT does not inhibit the γ-cleavage of APLP1. This result suggests that ApoE CT has a certain substrate selectivity in inhibiting the γ-secretase cleavage activity.

[0226] 3.8 Expression of ApoE CT in neurons can reduce amyloid plaques in the brains of AD model mice.

[0227] Adeno-associated virus (AAV) capable of expressing ApoECT in neurons was injected into the cortex and hippocampus of 4-week-old AD model mice (5×FAD). Six months later, ApoECT CT, GFP, and amyloid plaques were stained. Results showed that amyloid plaques in the brains of 5×FAD mice expressing ApoECT in neurons were smaller, had weaker fluorescence intensity, represented a smaller proportion of the total amyloid plaque area in the brain, and had a lower density. Figure 9 These results indicate that ApoE CT expressed in neurons can inhibit the deposition of amyloid plaques in the brains of 5×FAD mice.

[0228] 4. Experimental Conclusions

[0229] This invention is the first to discover that ApoE2 can regulate APP cleavage in neurons in a cell-autonomous manner, a process dependent on the C-terminal fragment of ApoE2. The C-terminal fragment of ApoE not only increases the non-amyloid metabolite α-CTF of APP, but also weakens APP amyloid metabolism, reducing Aβ. It was also found that ApoE2 and its C-terminal fragment regulate APP metabolism not by indirectly influencing APP cleavage in cells through secreted ApoE protein, but by directly inhibiting APP γ-cleavage via ApoE2 or its C-terminal fragment coexisting with APP in the same cell—a cell-autonomous mechanism of action. Experiments using purified protein also showed that ApoE2 can directly inhibit γ-secretase cleavage of β-CTF, while ApoE NT lacking the C-terminus cannot inhibit γ-secretase cleavage of β-CTF. Furthermore, the C-terminal fragment of ApoE cannot inhibit APLP1 γ-cleavage, indicating that the inhibitory effect of the C-terminal fragment of ApoE on γ-cleavage has substrate selectivity. The present invention also found that the C-terminal fragment of ApoE specifically expressed in neurons significantly reduced the size and density of amyloid plaques in the brains of AD model mice.

[0230] These results suggest that ApoE2 and its C-terminal fragment could serve as potential drugs for the prevention or treatment of Alzheimer's disease (AD). However, such potential drugs require a cell-autonomous mechanism of action within neurons. Liposome delivery of DNA or RNA, lentivirus and adeno-associated virus infection of cells, and other methods can enable the expression of ApoE2 and / or its C-terminal fragment in target cells. Cell-penetrating peptides and enhanced endocytosis can also lead to the abundant presence of ApoE2 and / or its C-terminal fragment within target cells. Consequently, ApoE2 and / or its C-terminal fragment can inhibit the enzymatic activity of γ-secretase, reduce Aβ, and weaken APP amyloid metabolism in a cell-autonomous manner.

[0231] The above experiment uses Alzheimer's disease (AD) as an example to illustrate how ApoE2 and / or its C-terminal fragment inhibit the enzymatic activity of γ-secretase in a cell-autonomous manner. Furthermore, conditions such as amyloidosis are also associated with abnormal γ-secretase function. Down syndrome is also prone to developing into AD. Therefore, ApoE2 and / or its C-terminal fragment also have potential applications in the treatment and prevention of these diseases. sequence list <110> Sleptay (Shanghai) Biomedical Technology Co., Ltd. <120> C-terminal fragment of apolipoprotein E and its application in inhibiting γ-secretase activity <130> 217334 <140> 202210113320.2 <141> 2022-01-30 <160> 45 <170> SIPOSequenceListing 1.0 <210> 1 <211> twenty one <212> DNA <213> Artificial Sequence <400> 1 agagcaacat ctggggacaa a 21 <210> 2 <211> twenty two <212> DNA <213> Artificial Sequence <400> 2 tccacaaata ggttggccag at 22 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <400> 3 gctctgggag agccaacata 20 <210> 4 <211> twenty one <212> DNA <213> Artificial Sequence <400> 4 aacgaattgg ctttgctgtc a 21 <210> 5 <211> twenty one <212> DNA <213> Artificial Sequence <400> 5 aggctatggt catgagggtt g 21 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <400> 6 tgactctctg catggtggtg 20 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <400> 7 tcagaattga gtgcagggct 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <400> 8 tttgagcctc ccttgactgg 20 <210> 9 <211> 19 <212> DNA <213> Artificial Sequence <400> 9 ggtattccag tccccgctg 19 <210> 10 <211> 21 <212> DNA <213> Artificial Sequence <400> 10 gattatctaa tggacgaccc c 21 <210> 11 <211> 21 <212> DNA <213> Artificial Sequence <400> 11 gcgtgcttcg ctccgtattt g 21 <210> 12 <211> 299 <212> PRT <213> Artificial Sequence <400> 12 Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu Arg Gln 1 5 10 15 Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu Gly Arg 20 25 30 Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln Val Gln 35 40 45 Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala Leu Met 50 55 60 Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu Glu Glu 65 70 75 80 Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser Lys Glu 85 90 95 Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp Val Cys 100 105 110 Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu Gly Gln 115 120 125 Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu 130 135 140 Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Cys Leu Ala 145 150 155 160 Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu Ser Ala 165 170 175 Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val Arg Ala 180 185 190 Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg Ala Gln 195 200 205 Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly Ser Arg 210 215 220 Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu Val Arg 225 230 235 240 Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala Glu Ala 245 250 255 Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu Asp Met 260 265 270 Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala Val Gly 275 280 285 Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His 290 295 <210> 13 <211> 85 <212> PRT <213> Artificial Sequence <400> 13 Arg Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp 1 5 10 15 Glu Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln 20 25 30 Ala Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys 35 40 45 Ser Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly 50 55 60 Leu Val Glu Lys Val Gln Ala Ala Val Gly Thr Ser Ala Ala Pro Val 65 70 75 80 Pro Ser Asp Asn His 85 <210> 14 <211> 86 <212> PRT <213> Artificial Sequence <400> 14 Leu Arg Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu 1 5 10 15 Asp Glu Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu 20 25 30 Gln Ala Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu 35 40 45 Lys Ser Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala 50 55 60 Gly Leu Val Glu Lys Val Gln Ala Ala Val Gly Thr Ser Ala Ala Pro 65 70 75 80 Val Pro Ser Asp Asn His 85 <210> 15 <211> 87 <212> PRT <213> Artificial Sequence <400> 15 Arg Leu Arg Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg 1 5 10 15 Leu Asp Glu Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu 20 25 30 Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg 35 40 45 Leu Lys Ser Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp 50 55 60 Ala Gly Leu Val Glu Lys Val Gln Ala Ala Val Gly Thr Ser Ala Ala 65 70 75 80 Pro Val Pro Ser Asp Asn His 85 <210> 16 <211> 88 <212> PRT <213> Artificial Sequence <400> 16 Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp 1 5 10 15 Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu 20 25 30 Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala 35 40 45 Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln 50 55 60 Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala Val Gly Thr Ser Ala 65 70 75 80 Ala Pro Val Pro Ser Asp Asn His 85 <210> 17 <211> 89 <212> PRT <213> Artificial Sequence <400> 17 Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg 1 5 10 15 Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys 20 25 30 Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln 35 40 45 Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg 50 55 60 Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala Val Gly Thr Ser 65 70 75 80 Ala Ala Pro Val Pro Ser Asp Asn His 85 <210> 18 <211> 83 <212> PRT <213> Artificial Sequence <400> 18 Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val 1 5 10 15 Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln 20 25 30 Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp 35 40 45 Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val 50 55 60 Glu Lys Val Gln Ala Ala Val Gly Thr Ser Ala Ala Pro Val Pro Ser 65 70 75 80 Asp Asn His <210> 19 <211> 82 <212> PRT <213> Artificial Sequence <400> 19 Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys 1 5 10 15 Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln 20 25 30 Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe 35 40 45 Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu 50 55 60 Lys Val Gln Ala Ala Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp 65 70 75 80 Asn His <210> 20 <211> 81 <212> PRT <213> Artificial Sequence <400> 20 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys 50 55 60 Val Gln Ala Ala Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn 65 70 75 80 His <210> 21 <211> 80 <212> PRT <213> Artificial Sequence <400> 21 Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln 1 5 10 15 Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg 20 25 30 Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro 35 40 45 Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val 50 55 60 Gln Ala Ala Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His 65 70 75 80 <210> 22 <211> 79 <212> PRT <213> Artificial Sequence <400> 22 Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val 1 5 10 15 Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu 20 25 30 Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu 35 40 45 Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln 50 55 60 Ala Ala Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His 65 70 75 <210> 23 <211> 79 <212> PRT <213> Artificial Sequence <400> 23 Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu 1 5 10 15 Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala 20 25 30 Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser 35 40 45 Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu 50 55 60 Val Glu Lys Val Gln Ala Ala Val Gly Thr Ser Ala Ala Pro Val 65 70 75 <210> 24 <211> 74 <212> PRT <213> Artificial Sequence <400> 24 Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu 1 5 10 15 Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala 20 25 30 Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser 35 40 45 Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu 50 55 60 Val Glu Lys Val Gln Ala Ala Val Gly Thr 65 70 <210> 25 <211> 71 <212> PRT <213> Artificial Sequence <400> 25 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys 50 55 60 Val Gln Ala Ala Val Gly Thr 65 70 <210> 26 <211> 70 <212> PRT <213> Artificial Sequence <400> 26 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys 50 55 60 Val Gln Ala Ala Val Gly 65 70 <210> 27 <211> 69 <212> PRT <213> Artificial Sequence <400> 27 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys 50 55 60 Val Gln Ala Ala Val 65 <210> 28 <211> 68 <212> PRT <213> Artificial Sequence <400> 28 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys 50 55 60 Val Gln Ala Ala 65 <210> 29 <211> 67 <212> PRT <213> Artificial Sequence <400> 29 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys 50 55 60 Val Gln Ala 65 <210> 30 <211> 66 <212> PRT <213> Artificial Sequence <400> 30 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys 50 55 60 Val Gln 65 <210> 31 <211> 61 <212> PRT <213> Artificial Sequence <400> 31 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu 50 55 60 <210> 32 <211> 56 <212> PRT <213> Artificial Sequence <400> 32 Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu 1 5 10 15 Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile 20 25 30 Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu 35 40 45 Pro Leu Val Glu Asp Met Gln Arg 50 55 <210> 33 <211> 84 <212> PRT <213> Artificial Sequence <400> 33 Ala Arg Met Glu Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu 1 5 10 15 Val Lys Glu Gln Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala 20 25 30 Gln Gln Ile Arg Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser 35 40 45 Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu 50 55 60 Val Glu Lys Val Gln Ala Ala Val Gly Thr Ser Ala Ala Pro Val Pro 65 70 75 80 Ser Asp Asn His <210> 34 <211> 60 <212> PRT <213> Artificial Sequence <400> 34 Glu Met Gly Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln 1 5 10 15 Val Ala Glu Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg 20 25 30 Leu Gln Ala Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro 35 40 45 Leu Val Glu Asp Met Gln Arg Gln Trp Ala Gly Leu 50 55 60 <210> 35 <211> 16 <212> PRT <213> Artificial Sequence <400> 35 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 36 <211> 11 <212> PRT <213> Artificial Sequence <400> 36 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 10 <210> 37 <211> 8 <212> PRT <213> Artificial Sequence <400> 37 Lys Gln Ala Ile Pro Val Ala Lys 1 5 <210> 38 <211> 15 <212> PRT <213> Artificial Sequence <400> 38 Arg Arg Arg Arg Asn Arg Thr Arg Arg Asn Arg Arg Arg Val Arg 1 5 10 15 <210> 39 <211> twenty one <212> PRT <213> Artificial Sequence <400> 39 Lys Leu Thr Arg Ala Gln Arg Arg Ala Ala Ala Arg Lys Asn Lys Arg 1 5 10 15 Asn Thr Arg Gly Cys 20 <210> 40 <211> twenty one <212> PRT <213> Artificial Sequence <400> 40 Ala Leu Trp Lys Thr Leu Leu Lys Lys Val Leu Lys Ala Pro Lys Lys 1 5 10 15 Lys Arg Lys Val Cys 20 <210> 41 <211> 9 <212> PRT <213> Artificial Sequence <400> 41 Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 <210> 42 <211> 34 <212> PRT <213> Artificial Sequence <400> 42 Asp Ala Ala Thr Ala Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr 1 5 10 15 Glu Arg Pro Arg Ala Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro 20 25 30 Val Glu <210> 43 <211> 27 <212> PRT <213> Artificial Sequence <400> 43 Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu 1 5 10 15 Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 20 25 <210> 44 <211> 21 <212> PRT <213> Artificial Sequence <400> 44 Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu Lys Ala Leu Ala Ala Leu 1 5 10 15 The Lys Lys Ile Leu 20 <210> 45 <211> 16 <212> PRT <213> Artificial Sequence <400> 45 Tyr Thr Ala Ila Trp Val Lys Ala Phe Ila Arg Lys Leu Arg Lys 1 5 10 15

Claims

1. An isolated polypeptide, characterized in that, The amino acid sequence of the polypeptide is as described in SEQ ID NO:13 or 18.

2. A nucleic acid molecule, selected from: (1) A nucleic acid molecule encoding the isolated polypeptide of claim 1; or (2) The full-length complementary sequences of the nucleic acid molecules described in (1).

3. A nucleic acid construct comprising the nucleic acid molecule of claim 2.

4. The nucleic acid construct as described in claim 3, characterized in that, The nucleic acid construct is an expression cassette, cloning vector, or expression vector.

5. A carrier, characterized in that, The vector contains a neuron-specific promoter and the coding sequence of the isolated polypeptide as described in claim 1.

6. The carrier as described in claim 5, characterized in that, The vector is a recombinant AAV expression vector.

7. The carrier as described in claim 5 or 6, characterized in that, The neuron-specific promoters are selected from synaptic protein promoters, Thy-1 promoters, and calmodulin-dependent protein kinase II-α promoters.

8. A host cell expressing the polypeptide of claim 1, and / or containing the nucleic acid molecule of claim 2, or the nucleic acid construct of claim 3 or 4, or the vector of any one of claims 5-7.

9. A pharmaceutical composition comprising the polypeptide of claim 1, the nucleic acid molecule of claim 2, or the nucleic acid construct of claim 3 or 4, or the carrier of any one of claims 5-7, and a pharmaceutically acceptable carrier.

10. The use of the polypeptide of claim 1, the nucleic acid molecule of claim 2, the nucleic acid construct of claim 3 or 4, the vector of any one of claims 5-7, the host cell of claim 8, or the pharmaceutical composition of claim 9 in the preparation of a medicament for treating diseases in which the enzymatic activity of γ-secretase is inhibited, wherein the disease is selected from: Alzheimer's disease, amyloidosis, and Down syndrome.

Citation Information

Patent Citations

  • Peptides for suppressing inflammation

    CN103429610A

  • Helical synthetic peptides that stimulate cellular cholesterol efflux

    US20050202532A1